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1 |  INTRODUCTION
This study offers a new treatment setup for external beam 
radiation therapy (EBRT) of the urethra carcinoma (UC) with 
reproducible supine technique obtained by homemade and 
personalized immobilization penis holder that at the same 
time, radiation dose to testicle can be reduced using testicular 
shield.
Urethra carcinoma (UC) is a rare form of urological can-
cers with a poor prognosis.1 In overall, UC makes up <1% 
of the total incidence of all malignant tumors.2 Although 
this malignancy occurs in both men and women, the inci-
dence of UC is approximately three times more in men than 
in women. As reported, the age-standardized rate (ASR) 
for UC is 1.6/million in men and 0.6/million in women.3 
Up to this date, owing to the rarity of UC, no prospective 
studies have been performed to determine the best treatment 
outcomes. Therefore, information about the treatment of 
UC and treatment outcomes is derived from retrospective 
studies or case series. As a consequence, an individualized 
treatment approach is adopted for this malignancy. The 
combination of radiation therapy and chemotherapy using 
5-FU and Mitomycin-C has been reported for locally ad-
vanced UC.4-6
In overall, the reproducibility of patient and target po-
sition between computed tomography (CT) planning and 
each treatment fraction is very important.7-9 In radiotherapy 
for the male UC, treatment setup is considered as a main 
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Abstract
A homemade personalized penis holder can provide the reproducibility of the penis 
during urethra carcinoma (UC) radiotherapy.
K E Y W O R D S
bolus, penis holder, silicon pellets, testicular shield, urethral cancer
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challenging issue owing to the variability in the penile posi-
tion. Any change in the anatomical position of the penis can 
reduce therapeutic ratio. The concept of radiotherapy for UC 
is similar to penile cancer radiotherapy. Therefore, external 
beam radiation therapy (EBRT) for UC is performed in the 
supine position. In addition, a wax block is used to support 
penis and spare surrounding normal tissues. There is a cen-
tral cavity into wax block that encased the penis vertically.6,10 
It should be noted, however, that there is some limitation in 
the aforementioned technique such as lack of availability of 
wax block in some centers and high median dose received by 
testis. To this end, we offer a new treatment setup for the UC 
EBRT with reproducible supine technique obtained by home-
made and personalized immobilization penis holder, and at 
the same time, it can reduce radiation dose to testicle using 
testicular shield.
2 |  CASE PRESENTATION
Our patient is a 30-year-old Asian male who had urethral 
obstruction, resulted in the inability to urinate. Hence, a 
suprapubic catheter was placed to drain urine. The pa-
tient underwent urethra biopsy by an expert urologist. A 
poorly differentiated urethral adenocarcinoma with inva-
sion to underlying smooth muscle and cavernous body 
(stage III, pT3cN0) has been indicated by tissue biopsy. 
In addition, the patient underwent chest-abdomen-pelvic 
CT with no evidence of metastatic disease. The patient 
underwent radiotherapy in two phases. In the first phase, 
the patient received a dose of 50 Gy (25 × 2 Gy) to prior 
prostatic urethra, whole penile shaft, bladder, prostatic 
urethral, and pelvic lymph nodes. In the second phase, a 
boost dose of 10 Gy (5 × 2 Gy) was delivered to the penile 
shaft and prostatic urethral. The patient received five cy-
cles of concurrent chemotherapy consisting of paclitaxel 
and cisplatin.
The median follow-up time was 25 months. Complete re-
sponse and local control were evaluated. Following radiother-
apy, the patient reported no urinary problems and he returned 
he came back to normal; however, he had penile numbness 
and penile skin erythematic.
2.1 | Simulation and immobilization
The patient underwent CT scan in the frog leg supine posi-
tion with a slice thickness of 3 mm. For immobilization of 
penis, we tailored a cylindrical holder based on diameter 
and length of our patient's penis size to encase the penis 
vertically. Cylindrical holder is made of silicon pellet bolus 
(Klarity, Medical Products), as shown in Figure 1A. Silicon 
pellet bolus is soften in the water bath. Then, we formed it as 
penis holder. Holder had 8 cm length, 3 cm inner diameter, 
and 0.8 cm wall thickness (Figure 1B,C).
For reducing radiation dose to the testis, we used a testicu-
lar shield in the simulation and treatment fractions. The shield 
had hemispherical shape with an inner radius of 3.25 cm, a 
maximum depth of 3.5  cm at the center, and 1.5  cm wall 
thickness. The inner surface of the shield is coated with a 
thin layer of dental wax coating to give a smooth surface and 
reduce backscattered radiation dose from the shield.
The patient underwent two consecutive CT scans in the 
frog leg supine position, with testicular shield and penis 
holder (as displayed in Figure  2) and then without a tes-
ticular shield to remove the metal artifact. A radio-opaque 
marker is placed on the patient skin by the responsible 
physician.
F I G U R E  1  Silicon pellet bolus before soften in water bath (A). Cylindrical holder is made of silicon pellet bolus, (B) top view, and (C) lateral 
view
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2.2 | Contouring and treatment planning
Computed tomography datasets were imported into the Eclipse 
treatment planning system version 13.7 (Varian Medical 
System). The clinical target volume (CTV) of pelvic lymph 
nodes (called CTVLN) included common iliac, obturator, and 
external and internal iliac. The high-risk CTV (CTVH) included 
prostatic and penile urethra. All target volumes were delineated 
by responsible radiation oncologist on the CT dataset without 
testicular shield. Also, all contours were rechecked by two radi-
ation oncologists. Planning target volume (PTV) for first phase 
of radiotherapy was defined as CTVLN plus a 7-mm margin and 
CTVH plus a 1-cm margin. PTV of phase 2 of radiotherapy was 
defined as CTVH plus a 1-cm margin. Furthermore, all contours 
were copied on CT scan with testicular shields and dose calcu-
lation was done on both CT scans.
We apply the four-field box technique (field at 0°, 90°, 
180°, and 270°). A field in field technique was used to maxi-
mize dose coverage of PTV and spare as much as possible the 
rectum, bladder, and testis. Figure 3 shows the dose distribu-
tion in sagittal and axial views.
Prior to each treatment fraction, the patient was positioned 
at the same position in the CT simulation with penis holder 
and testicular shield to increase reproducibility of patient po-
sition in each fraction and correct position of penile holder 
marked on skin of patient in first treatment session. Online 
correction of the pelvic bony marker was performed by an 
electronic portal imaging device (EPID). Average total time 
for patient positioning and imaging by EPID before treatment 
delivery was approximately 6  minutes. The patient had no 
problem with maintaining stability for the position in simula-
tion and treatment delivery.
3 |  DISCUSSION
This report aimed to propose a new treatment setup for the 
UC EBRT with reproducible supine technique obtained by 
homemade and personalized immobilization penis holder, 
and at the same time, it can reduce radiation dose to tes-
ticle using testicular shield. To the best of our knowledge, 
our reported technique for EBRT of UC has not been previ-
ously described in the literature. Different approaches can 
be used for patient setup during radiotherapy for the penis 
in the UC.6,11 In the traditional setup technique for EBRT 
of the penile urethra, patient was positioned in the supine 
position using 10  ×  10  cm2 wax block that encases penis 
vertically.10,11 Using the aforementioned technique can be 
more uncomfortable for the patient during EBRT, and also 
this method does not result in an effective reduction in the 
mean dose received by testis during radiotherapy course.11 
In addition, wax block cannot provide a personalized im-
mobilization of the penis owing to the different anatomy of 
the patients. Another limitation of wax block is lack of avail-
ability in some centers.
In our proposed technique, we used silicon pellet bolus 
that is low price material and available in each radiation 
therapy department. We have built a penis holder with 
silicon pellet bolus exclusively for each patient based on 
penile size and diameter, and also we can increase the 
F I G U R E  2  Patient's position for CT simulation, with testicular 
shield and penis holder in the frog legs position
F I G U R E  3  Dose distribution of 95% in axial (A) and sagittal views (B)
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reproducibility of the patient setup. Another advantage of 
our method is that a testicular shield can be used at the 
same time with the penis holder. In addition, dose received 
by testis was calculated in CT scans with and without tes-
ticular shield using Eclipse treatment planning system. 
The mean dose received by testis with and without the tes-
ticular shield was 6.5 Gy and 28 Gy, respectively. Figure 4 
shows the organs at risk and PTV dose-volume histogram 
with the testicular shield.
Nowadays, three-dimensional (3D) printing technology 
has been used in radiation oncology to fabricate personal-
ized and customized treatment accessories such as bolus, 
brachytherapy applicators, immobilizers, and compensa-
tors.12,13 Therefore, our proposed immobilization penis 
holder can be fabricated by 3D printing. Another radiother-
apy approach that can be used to treat UC is brachytherapy. 
Of note, brachytherapy is invasive and has more side effects, 
as compared to EBRT.14
In conclusion, our proposed technique is a novel prom-
ising approach that can result in increasing reproducibility 
of the penis position. It can be also used for other penis ma-
lignancies. This report offers an innovative technique for 
sparing testis in EBRT of UC and penis malignancy, indicat-
ing cost-effectiveness, simplicity, and reproducibility of our 
method. Larger studies are warranted to evaluate the potential 
adverse effects associated with this method.
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